04/02/2019
Newsletters of Interest
A Few Articles You Won’t Want to Miss:
- Changes to our National Precertification List (NPL)
- Changes to commercial drug lists begin on July 1, 2019
And Much More….MARCH OfficeLink Updates Qtly Issue Available HERE
A Few Articles You Won’t Want to Miss:
- Clinical review decisions are based solely on appropriateness of care
- Network guidelines for member access
- BCN medical directors are a resource for physicians
- Medical policy updates
- Blue Care Network evaluates appropriateness of E&M coding
- Starting May 1, additional radiology services require authorization by AIM for BCN and Blue Cross members
And Much More…MARCH/APRIL Bi-Monthly Issue Available HERE
Current Issue Available HERE
Current Issue Available HERE
(Once on the site, scroll to the bottom and choose NEWS on the left side)
A Few Articles You Won’t Want to Miss:
- Humana Updates Preauthorization and Notification Lists for 2019
- Changes Announced for 2019 Humana Formularies
- New and Revised Pharmacy and Medical Coverage Policies Available
And Much More…Latest Issue Available HERE
A Few Articles You Won’t Want to Miss:
- Front & Center
- Updates to Requirements for Specialty Medical Injectable Drugs for UnitedHealthcare Commercial, Community Plan and Medicare Advantage Members
- Changes in Advance Notification and Prior Authorization Requirements
- More Fax Numbers Used for Medical Prior Authorization Will Retire July 1, 2019
- Prior Authorization Required for Therapeutic Radiopharmaceuticals
And Much More…APRIL Monthly Issue Available HERE
Oncology Related Articles You Won’t Want to Miss:
Medical Policy Updates
Updated:
- Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions – Effective Apr. 1, 2019
Medical Benefit Drug Policy Updates
Updated:
- Clotting Factors, Coagulant Blood Products & Other Hemostatics – Effective Apr. 1, 2019
- Infliximab (Remicade®, Inflectra™, Renflexis™) – Effective Apr. 1, 2019
- Ketamine – Effective Apr. 1, 2019
- Self-Administered Medications List – Effective Apr. 1, 2019
- Trogarzo™ (Ibalizumab-Uiyk) – Effective Apr. 1, 2019
Revised:
- Actemra® (Tocilizumab) Injection for Intravenous Infusion – Effective Apr. 1, 2019
- Denosumab (Prolia® & Xgeva®) – Effective Apr. 1, 2019
- Ocrevus™ (Ocrelizumab) – Effective Apr. 1, 2019
- Orencia® (Abatacept) Injection for Intravenous Infusion – Effective Apr. 1, 2019
- Rituximab (Rituxan® & Truxima®) – Effective Apr. 1, 2019
- Simponi Aria® (Golimumab) Injection for Intravenous Infusion – Effective Apr. 1, 2019
- Stelara® (Ustekinumab) – Effective Apr. 1, 2019
Utilization Review Guideline (URG) Updates
Revised:
- Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Scan – Site of Care – Effective Apr. 1, 2019
APRIL Monthly Issue Available HERE